PDP Preferred Provider Agreement for Triclinium
Triclinium, a Clinical Research Organisation (CRO) headquartered in Johannesburg, South Africa, has been selected as a Preferred Provider for clinical trial support services to 14 Product Development Partnerships (PDPs).
These PDPs are non-profit organisations mandated to research and deliver therapies and vaccines for diseases that commonly afflict the world’s poorer nations, including tuberculosis, malaria, HIV/AIDS, leishmaniasis and sleeping sickness. The 14 PDPs, which are all partially funded by the Bill & Melinda Gates Foundation, have a rich combined product pipeline that will be developed in over 120 planned Phase I to IV clinical trials scheduled for initiation by Q4 2012.
“Triclinium is honoured to be one of only 6 Contract Research Organisations worldwide – and the only wholly African CRO – selected by the PDPs,” says Victor Strugo, founder and Managing Director of Triclinium.
“Having already worked extensively with 4 PDPs over the last 8 years, this Preferred Provider status significantly reaffirms our conscious commitment to supporting research focused on the major health issues and neglected diseases of our native continent. We look forward to supporting more PDP research into major global health challenges, in and beyond the 12 countries in which we already have research experience.”
Triclinium (www.triclinium.net) is a wholly South African CRO, established in Johannesburg in February 2000 around the core functions of clinical trial set-up, regulatory, monitoring, management and auditing across sub-Saharan Africa. Its track-record spans 168 clinical trials for 60 clients of 19 nationalities (repeat business rate 78%) involving more than 40,000 participants at 540 sites across 14 therapeutic areas in Phases I-IV.
The company has an extensive database of experienced investigators in multiple therapeutic areas and has also established strong and seamless collaborations with several other specialist and regional vendors, whereby full-service solutions are effectively tailored to specific requirements.
Triclinium is positioned as an effective gateway to the sub-Saharan region’s massive enrolment potential in first and third world indications and has proven capabilities of significantly contributing to enrolment in global clinical trials.
- Contact Information
- Victor Strugo
- Managing Director
- Triclinium Clinical Trial Project Management
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.